FEB 2015


February 2015, Lausanne, Switzerland:  InterAx was two of four companies selected by a jury of successful entrepreneurs and investors to win 10,000 CHF in pre-seed capital. The company will now move on to Stage II of the Venture Kick competition, with an opportunity to win an additional 20,000 CHF.


DEC 2014

Dr. Martin Ostermaier named Pioneer Fellow, InterAx Biotech awarded 150,000 CHF in equity free capital


December 2014, Zürich, Switzerland: InterAx Biotech Co-Founder Martin Ostermaier was selected by a panel of scientific experts as an ETH Zürich Pioneer Fellow. The award was given based on the scientific merit of the arrestin-GPCR complex stabilization technology and its potential in drug screening applications.